Associations of maternal and infant metabolite profiles with foetal growth and the odds of adverse birth outcomes.

Abstract

SummaryBackgroundAdaptations in maternal and foetal metabolic pathways may predispose to altered foetal growth and adverse birth outcomes.ObjectiveTo assess the associations of maternal early‐pregnancy metabolite profiles and infant metabolite profiles at birth with foetal growth from first trimester onwards and the odds of adverse birth outcomes.MethodsIn a prospective population‐based cohort among 976 Dutch pregnant women and their children, serum concentrations of amino acids, non‐esterified fatty acids (NEFA), phospholipids (PL) and carnitines in maternal early‐pregnancy blood and in cord blood were obtained by liquid‐chromatography tandem mass spectrometry. Information on foetal growth was available from first trimester onwards.ResultsAfter false discovery rate correction for multiple testing, higher infant total and individual NEFA concentrations were associated with a lower weight, length, and head circumference at birth. Higher infant total and individual acyl‐lysophosphatidylcholine (lyso.PC.a) and alkyl‐lysophosphatidylcholine concentrations were associated with higher weight and head circumference (lyso.PC.a only) at birth, higher odds of LGA and lower odds of SGA. Few individual maternal metabolites were associated with foetal growth measures in third trimester and at birth, but not with the odds of adverse birth outcomes.ConclusionsOur results suggest that infant metabolite profiles, particularly total and individual lyso.PC.a and NEFA concentrations, were strongly related to growth measures at birth and the odds of adverse birth outcomes. Few individual maternal early‐pregnancy metabolites, but not total metabolite concentrations, are associated with foetal growth measures in third trimester and at birth.